JP2024517642A5 - - Google Patents

Info

Publication number
JP2024517642A5
JP2024517642A5 JP2023564119A JP2023564119A JP2024517642A5 JP 2024517642 A5 JP2024517642 A5 JP 2024517642A5 JP 2023564119 A JP2023564119 A JP 2023564119A JP 2023564119 A JP2023564119 A JP 2023564119A JP 2024517642 A5 JP2024517642 A5 JP 2024517642A5
Authority
JP
Japan
Prior art keywords
amino acid
viral protein
modified
parent
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517642A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/060417 external-priority patent/WO2022223617A1/en
Publication of JP2024517642A publication Critical patent/JP2024517642A/ja
Publication of JP2024517642A5 publication Critical patent/JP2024517642A5/ja
Pending legal-status Critical Current

Links

JP2023564119A 2021-04-20 2022-04-20 ウイルスワクチン Pending JP2024517642A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2021/060273 2021-04-20
EP2021060273 2021-04-20
PCT/EP2022/060417 WO2022223617A1 (en) 2021-04-20 2022-04-20 Virus vaccine

Publications (2)

Publication Number Publication Date
JP2024517642A JP2024517642A (ja) 2024-04-23
JP2024517642A5 true JP2024517642A5 (cg-RX-API-DMAC7.html) 2025-04-25

Family

ID=81579467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564119A Pending JP2024517642A (ja) 2021-04-20 2022-04-20 ウイルスワクチン

Country Status (11)

Country Link
US (1) US20240383947A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326317A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024517642A (cg-RX-API-DMAC7.html)
KR (1) KR20240009419A (cg-RX-API-DMAC7.html)
CN (1) CN117750974A (cg-RX-API-DMAC7.html)
AU (1) AU2022260466A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021654A2 (cg-RX-API-DMAC7.html)
CA (1) CA3215771A1 (cg-RX-API-DMAC7.html)
IL (1) IL307762A (cg-RX-API-DMAC7.html)
MX (1) MX2023012368A (cg-RX-API-DMAC7.html)
WO (1) WO2022223617A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN117153245B (zh) * 2023-10-18 2024-03-19 无锡市疾病预防控制中心 预测新型冠状病毒S蛋白RBD区域与hACE2受体相互作用的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
DK2046826T3 (da) 2006-07-24 2011-10-24 Biorexis Pharmaceutical Corp Exendin-fusionsproteiner
US20100113339A1 (en) 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
AU2008345424A1 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
CN102076713B (zh) 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
WO2011051478A1 (en) 2009-10-30 2011-05-05 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
DK2558491T3 (en) 2010-04-13 2018-10-15 Bristol Myers Squibb Co Fibronectin-based Scaffold domain proteins that bind PCSK9
EP2758436B1 (en) 2011-09-23 2019-06-12 Universität Stuttgart Serum half-life extension using immunoglobulin binding domains
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
MA46023A (fr) * 2015-10-22 2019-07-03 Modernatx Inc Vaccin contre le virus de la grippe à large spectre

Similar Documents

Publication Publication Date Title
BR0312935A (pt) Partìcula semelhante a vìrus, muteìna, vetores para produzir a referida partìcula e proteìna recombinante, composição, processo para produção de fileira ordena e repetitva de antìgeno, molécula de ácido nucléico, célula hospedeira, método para produção da referida partìcula e uso da composição de vacina
JP2016539944A (ja) 新規sars免疫原性組成物
CN105431535A (zh) 疟疾疫苗
JP2014507146A5 (cg-RX-API-DMAC7.html)
US20250339511A1 (en) Nucleic acid vaccine against monkeypox virus and use thereof
Bassel-Duby et al. Evidence that the sigma 1 protein of reovirus serotype 3 is a multimer
IL307762A (en) Vaccine against viruses
WO2011062625A2 (en) Physicochemical (pcp) based consensus sequences and uses thereof
US20220054625A1 (en) Immunogenic composition
Wibowo et al. Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes
CN118340875A (zh) 一种水痘-带状疱疹病毒的mRNA疫苗及其应用
WO2024055273A1 (zh) 一种狂犬病mRNA疫苗、其制备及应用
JP6863966B2 (ja) 標的ポリペプチドを提示するためのポリペプチド担体及びその使用
CN101451145A (zh) 基于t细胞表位的结核基因疫苗及其制备方法和应用
JP2020515241A (ja) 標的ポリペプチドを提示するためのポリペプチド担体及びその使用
JP5473899B2 (ja) 合成ペプチドを含有する抗原薬物ビークルとこれを用いる粘膜ワクチン
AU2016201589B2 (en) Peptide adjuvants
US20240261389A1 (en) Amino acids, nucleotides and vectors expressing the same and uses thereof in preventing sarbecovirus infection
Liao et al. Integration of novel materials and advanced genomic technologies into new vaccine design
US20080026008A1 (en) Bacteriophage DNA vaccine vector
DE60035485D1 (de) IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407
EP4415748A1 (en) Multiepitope self-assembled nanoparticle vaccine platform (msn-vaccine platform) and uses there of
JP2005082581A (ja) 分泌型IgA抗体誘導剤
WO2007104263A1 (zh) 一种乙型肝炎病毒疫苗增效蛋白及其基因
JPH07170982A (ja) ワクチンおよびその製造方法